Lumida
/ATROB
⌘K
ATROB

ATROB

ATROB
$67.01USD+1.78%+1.17 today

MARKET CAP

2.9B

P/E (TTM)

94.4x

FWD P/E

22.5x

DAY RANGE

$64 – $68

52W RANGE

$23
$91

AI Summary

Stalk
TrimMedium

ATROB remains in a Stage 4 decline with medium-term bearish asymmetry. The asset is trading below the 9 EMA, 21 EMA, and 50 DMA, with failed rally attempts indicating persistent selling pressure. Although a Bearish Exhaustion pattern suggests potential stabilization, overall momentum and Stage 4 context favor continued downtrend. Execution should be deferred to rallies into short-term EMA resistance zones for trimming positions.

  • Q1 EPS $0.59 vs $0.57 est and revenue $231M vs $227.8M est
  • Analysts expect ~7.1% annual revenue growth to $1.1B by 2029
  • P/E ratio 76.4x markedly above aerospace & defense avg of 40.3x
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Astronics Corporation (NASDAQ: ATROB) is a leading provider of advanced aerospace and defense technologies, specializing in electrical power and lighting systems, along with test equipment and integrated solutions. The company operates primarily within the aerospace and defense sector, a domain characterized by rigorous demand for innovation and regulatory compliance. Recent developments, including an extensive contract with the U.S. Army and strong Q1 earnings, highlight its dominant market position and potential growth trajectory amidst increasing military expenditures.

Bull says

  • Q1 EPS $0.59 vs $0.57 est and revenue $231M vs $227.8M est
  • Analysts expect ~7.1% annual revenue growth to $1.1B by 2029
  • 1.2-for-1 stock split improved visibility at recent investor events
  • Dividend yield 0.66% and high institutional ownership support stability
  • Divesting low-margin lines to focus on high-margin aerospace products
  • $44.7M Army contract underlines defense segment tailwinds

Bear says

  • P/E ratio 76.4x markedly above aerospace & defense avg of 40.3x
  • Negative profitability profile and high leverage heighten financial risk
  • Execution risk in Test segment may strain margins and growth
  • Tariff and regulatory exposure could unpredictably impact costs and revenue
  • After-hours drop from all-time highs signals correction risk
  • Overvaluation concerns may deter investors if growth misses estimates